US6218160B1
(en)
*
|
1997-10-31 |
2001-04-17 |
Roche Diagnostics Corporation |
Site-specific conjugation of glycoproteins
|
WO2000006543A1
(fr)
*
|
1998-07-29 |
2000-02-10 |
Chisso Corporation |
Nouveaux composes diamino, polyamide d'acide, polyimide, film d'alignement a cristaux liquides forme d'un film du polyimide et element d'affichage a cristaux liquides contenant le film d'alignement
|
EP1889639A3
(en)
*
|
1999-09-07 |
2008-04-09 |
ConjuChem Biotechnologies Inc. |
Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents
|
CA2383798A1
(en)
*
|
1999-09-07 |
2001-03-15 |
Conjuchem Inc. |
Pulmonary delivery for bioconjugation
|
US6706892B1
(en)
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
ES2552281T3
(es)
|
2001-05-11 |
2015-11-26 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específica y usos de las mismas
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
NZ511705A
(en)
*
|
2001-05-14 |
2004-03-26 |
Horticulture & Food Res Inst |
Methods and rapid immunoassay device for detecting progesterone and other steroids
|
US7129261B2
(en)
*
|
2001-05-31 |
2006-10-31 |
Medarex, Inc. |
Cytotoxic agents
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
AU2003250151A1
(en)
*
|
2002-07-24 |
2004-02-16 |
Diatos S.A. |
Method for the synthesis of anthracycline-peptide conjugates
|
US20040047917A1
(en)
*
|
2002-09-06 |
2004-03-11 |
Stephen Wilson |
Drug delivery and targeting with vitamin B12 conjugates
|
AU2011236095B2
(en)
*
|
2003-01-24 |
2013-08-01 |
Immunomedics, Inc. |
Anthracycline-antibody conjugates
|
US20040202666A1
(en)
*
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
US7662387B2
(en)
|
2003-02-20 |
2010-02-16 |
Seattle Genetics |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US7053191B2
(en)
*
|
2003-05-21 |
2006-05-30 |
Solux Corporation |
Method of preparing 4-R-substituted 4-demethoxydaunorubicin
|
US20060204442A1
(en)
*
|
2003-09-12 |
2006-09-14 |
Bankruptcy Estate Of Ferx, Inc. |
Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
|
CA2564076C
(en)
*
|
2004-05-19 |
2014-02-18 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
RU2402548C2
(ru)
*
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
US7541330B2
(en)
*
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
WO2006015318A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Biogen Idec Inc. |
Antibody conjugated to a drug moiety via a poptidic linker
|
ATE476994T1
(de)
|
2004-11-30 |
2010-08-15 |
Curagen Corp |
Antikörper gegen gpnmb und ihre verwendungen
|
CA2598522A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen (psma)
|
ATE476655T1
(de)
*
|
2005-03-30 |
2010-08-15 |
Saladax Biomedical Inc |
Doxorubicin-immuntest
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
WO2007038658A2
(en)
*
|
2005-09-26 |
2007-04-05 |
Medarex, Inc. |
Antibody-drug conjugates and methods of use
|
JP5116686B2
(ja)
|
2005-10-26 |
2013-01-09 |
メダレックス インコーポレイテッド |
Cc−1065類似体の調製方法及び調製用化合物
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
KR101071516B1
(ko)
|
2006-05-05 |
2011-10-10 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
2가 smac 모방체 및 그의 용도
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
JP5276017B2
(ja)
|
2007-01-25 |
2013-08-28 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Egfr変異体仲介性疾患の治療における抗egfr抗体の使用
|
JP2010519310A
(ja)
|
2007-02-21 |
2010-06-03 |
メダレックス インコーポレイテッド |
単一のアミノ酸を有する化学リンカーおよびその複合体
|
WO2008115404A1
(en)
|
2007-03-15 |
2008-09-25 |
Ludwing Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
JP5779350B2
(ja)
|
2007-03-27 |
2015-09-16 |
シー レーン バイオテクノロジーズ, エルエルシー |
抗体代替軽鎖配列を含む構築物およびライブラリー
|
JP5532486B2
(ja)
|
2007-08-14 |
2014-06-25 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途
|
AU2008308509B2
(en)
|
2007-10-04 |
2014-10-23 |
Zymogenetics, Inc. |
B7 family member zB7H6 and related compositions and methods
|
US8357785B2
(en)
*
|
2008-01-08 |
2013-01-22 |
Solux Corporation |
Method of aralkylation of 4′-hydroxyl group of anthracylins
|
CA2711736A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
CA2761681A1
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
CA2774032C
(en)
|
2009-10-23 |
2019-03-26 |
Millennium Pharmaceuticals, Inc. |
Anti-gcc antibody molecules and related compositions and methods
|
WO2011070443A1
(en)
|
2009-12-09 |
2011-06-16 |
Institut National De La Sante Et De La Recherche Medicale |
Monoclonal antibodies that bind b7h6 and uses thereof
|
JP6046494B2
(ja)
|
2010-02-08 |
2016-12-14 |
アジェンシス,インコーポレイテッド |
161p2f10bタンパク質に結合する抗体薬物コンジュゲート(adc)
|
JP5953303B2
(ja)
|
2010-07-29 |
2016-07-20 |
ゼンコア インコーポレイテッド |
改変された等電点を有する抗体
|
TW202344270A
(zh)
|
2010-09-29 |
2023-11-16 |
美商艾澤西公司 |
與191p4d12蛋白結合之抗體藥物共軛物(adc)
|
EP2621954A1
(en)
|
2010-10-01 |
2013-08-07 |
Oxford Biotherapeutics Ltd. |
Anti-rori antibodies
|
PT3156420T
(pt)
|
2010-12-06 |
2019-05-27 |
Seattle Genetics Inc |
Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
US8846882B2
(en)
|
2011-04-29 |
2014-09-30 |
Synbias Pharma Ag |
Method of producing 4-demethoxydaunorubicin
|
DK3415531T3
(da)
|
2011-05-27 |
2023-09-18 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17)-bindende proteiner
|
CA2842860A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies, Llc |
Sur-binding proteins
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
EP3611187A1
(en)
|
2011-10-10 |
2020-02-19 |
Xencor, Inc. |
A method for purifying antibodies
|
WO2013063702A1
(en)
|
2011-11-04 |
2013-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
CA2859744A1
(en)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Surrogate binding proteins
|
EP2794653B1
(en)
|
2011-12-23 |
2019-03-13 |
Pfizer Inc |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
AU2013209512B2
(en)
|
2012-01-20 |
2017-08-03 |
I2 Pharmaceuticals, Inc. |
Surrobody cojugates
|
ES2812849T3
(es)
|
2012-02-24 |
2021-03-18 |
Abbvie Stemcentrx Llc |
Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
|
WO2013173337A2
(en)
|
2012-05-15 |
2013-11-21 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
TWI606063B
(zh)
|
2012-08-23 |
2017-11-21 |
艾澤西公司 |
結合至158p1d7蛋白之抗體藥物結合物(adc)
|
CN105849086B
(zh)
|
2012-11-24 |
2018-07-31 |
杭州多禧生物科技有限公司 |
亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
KR102211837B1
(ko)
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US8877202B2
(en)
|
2013-02-07 |
2014-11-04 |
Immunomedics, Inc. |
Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
|
ME03394B
(me)
|
2013-02-22 |
2020-01-20 |
Medimmune Ltd |
Antidllз-antitelo-pbd konjugati i nihovа upotreba
|
CA3093606A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Heterodimeric proteins for induction of t cells
|
EP3587448B1
(en)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
WO2014194030A2
(en)
*
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
SG11201600587VA
(en)
|
2013-08-01 |
2016-02-26 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to cd37 proteins
|
AU2014312215B2
(en)
|
2013-08-28 |
2020-02-27 |
Abbvie Stemcentrx Llc |
Site-specific antibody conjugation methods and compositions
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
CN105745224B
(zh)
|
2013-10-11 |
2019-11-05 |
牛津生物疗法有限公司 |
用于治疗癌症的针对ly75的偶联抗体
|
CA3178299A1
(en)
|
2013-10-11 |
2015-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tem8 antibodies and their use
|
KR102645430B1
(ko)
|
2013-10-15 |
2024-03-11 |
씨젠 인크. |
개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
SG10201710475WA
(en)
|
2013-11-25 |
2018-01-30 |
Seattle Genetics Inc |
Preparing antibodies from cho cell cultures for conjugation
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
AU2015205756A1
(en)
|
2014-01-10 |
2016-07-21 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for treating EGFR expressing tumors
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체
|
DK3122757T3
(da)
|
2014-02-28 |
2023-10-09 |
Hangzhou Dac Biotech Co Ltd |
Ladede linkere og anvendelse deraf til konjugering
|
CA2942101A1
(en)
|
2014-03-21 |
2015-09-24 |
Abbvie Inc. |
Anti-egfr antibodies and antibody drug conjugates
|
AU2015237200A1
(en)
|
2014-03-27 |
2016-10-06 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
KR20230022270A
(ko)
|
2014-03-28 |
2023-02-14 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
CN105440135A
(zh)
|
2014-09-01 |
2016-03-30 |
博笛生物科技有限公司 |
用于***的抗-pd-l1结合物
|
EP3194449A1
(en)
|
2014-07-24 |
2017-07-26 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
ES2848376T3
(es)
|
2014-11-19 |
2021-08-09 |
Axon Neuroscience Se |
Anticuerpos de tau humanizados en la enfermedad de Alzheimer
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3及びcd38に結合するヘテロ二量体抗体
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
EP3223845B1
(en)
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US10472395B2
(en)
|
2015-03-05 |
2019-11-12 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
CA2978631C
(en)
|
2015-03-09 |
2023-06-27 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
ES2961346T3
(es)
|
2015-06-12 |
2024-03-11 |
Lentigen Tech Inc |
Procedimiento para tratar cáncer con células T modificadas genéticamente
|
US11351269B2
(en)
|
2015-06-30 |
2022-06-07 |
Seagen Inc. |
Anti-NTB-A antibodies and related compositions and methods
|
EP3319936A4
(en)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
EP3347047A1
(en)
|
2015-09-09 |
2018-07-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Expression vector delivery system and use thereof for inducing an immune response
|
WO2017062748A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
EP3660044A1
(en)
|
2015-10-09 |
2020-06-03 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
WO2017147597A1
(en)
|
2016-02-27 |
2017-08-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptide vaccines comprising self-assembling polymer nanoparticles
|
KR102445255B1
(ko)
|
2016-03-02 |
2022-09-22 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
에리불린-기반 항체-약물 콘주게이트 및 사용 방법
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
KR102626498B1
(ko)
|
2016-03-25 |
2024-01-19 |
씨젠 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
TW201805309A
(zh)
|
2016-04-21 |
2018-02-16 |
艾伯維史坦森特瑞斯有限責任公司 |
新穎抗-bmpr1b抗體及使用方法
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
IL300274A
(en)
|
2016-06-08 |
2023-04-01 |
Abbvie Inc |
Antibodies against B7–H3 and conjugates of drug and antibody
|
AU2017277914A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-CD98 antibodies and antibody drug conjugates
|
BR112018075653A2
(pt)
|
2016-06-08 |
2019-08-27 |
Abbvie Inc |
anticorpos anti-b7-h3 e conjugados anticorpo fármaco
|
CN109641962A
(zh)
|
2016-06-08 |
2019-04-16 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
CA3027046A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
WO2017218707A2
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
CA3032147A1
(en)
|
2016-08-09 |
2018-02-15 |
Seattle Genetics, Inc. |
Drug conjugates with self-stabilizing linkers having improved physiochemical properties
|
US11254705B2
(en)
|
2016-09-02 |
2022-02-22 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
CA3035615A1
(en)
|
2016-09-02 |
2018-03-08 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
US10501543B2
(en)
|
2016-10-14 |
2019-12-10 |
Xencor, Inc. |
IL15/IL15Rα heterodimeric Fc-fusion proteins
|
WO2018086139A1
(en)
|
2016-11-14 |
2018-05-17 |
Hangzhou Dac Biotech Co., Ltd |
Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
|
US10183993B2
(en)
|
2017-01-09 |
2019-01-22 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
JP2020510432A
(ja)
|
2017-03-02 |
2020-04-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nectin−4への特異性を有する抗体及びその使用
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
JP2020512312A
(ja)
|
2017-03-24 |
2020-04-23 |
シアトル ジェネティックス, インコーポレイテッド |
グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
|
WO2018175988A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
CA3057715A1
(en)
|
2017-04-04 |
2018-10-11 |
Avidea Technologies, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
MX2019012017A
(es)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics Inc |
Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
AU2018259856A1
(en)
|
2017-04-28 |
2019-11-14 |
Ajinomoto Co., Inc. |
Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
AU2018309735A1
(en)
|
2017-07-31 |
2020-02-20 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
TW201919712A
(zh)
|
2017-08-10 |
2019-06-01 |
法商塞勒尼斯醫療控股公司 |
運送子(cargomers)
|
CA3075915A1
(en)
|
2017-09-15 |
2019-03-21 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19 immunotherapy
|
ES2958849T3
(es)
|
2017-10-16 |
2024-02-15 |
Lentigen Tech Inc |
Composiciones y métodos para tratar el cáncer con inmunoterapia anti-CD22
|
JP7381478B2
(ja)
|
2017-10-23 |
2023-11-15 |
マブリンク ビオシオンス |
単一分子量ポリサルコシンを含むリガンド-薬物-複合体
|
US10386338B2
(en)
|
2017-10-30 |
2019-08-20 |
Cynthia Rena Wright |
DNA/RNA PEMS microcantilever probe for detection of viral infection and detection of genetic variants
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
MX2020005640A
(es)
|
2017-12-01 |
2020-08-20 |
Seattle Genetics Inc |
Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
|
MX2020005463A
(es)
|
2017-12-01 |
2020-09-07 |
Seattle Genetics Inc |
Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
|
KR20200100098A
(ko)
|
2017-12-19 |
2020-08-25 |
젠코어 인코포레이티드 |
조작된 il-2 fc 융합 단백질
|
CA3086612A1
(en)
|
2017-12-20 |
2019-06-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating hiv/aids with immunotherapy
|
US20210024628A1
(en)
|
2018-03-22 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
JP2021518397A
(ja)
|
2018-03-23 |
2021-08-02 |
シージェン インコーポレイテッド |
固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用
|
MX2020009991A
(es)
|
2018-03-28 |
2020-10-14 |
Axon Neuroscience Se |
Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
AU2019272844A1
(en)
|
2018-05-22 |
2021-01-21 |
Barinthus Biotherapeutics North America, Inc. |
Improved methods of manufacturing peptide-based vaccines
|
CA3099920A1
(en)
|
2018-06-01 |
2019-12-05 |
Eisai R&D Management Co., Ltd. |
Splicing modulator antibody-drug conjugates and methods of use
|
CN112261954A
(zh)
|
2018-06-14 |
2021-01-22 |
味之素株式会社 |
具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
|
EP3808760A4
(en)
|
2018-06-14 |
2022-10-05 |
Ajinomoto Co., Inc. |
COMPOUND WITH AFFINITY FOR ANTIBODY, CLEAVAGE SITE AND REACTIVE GROUP OR SALT THEREOF
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
EP3817770A2
(en)
|
2018-07-02 |
2021-05-12 |
Amgen Inc. |
Anti-steap1 antigen-binding protein
|
AU2019343184A1
(en)
|
2018-09-20 |
2021-04-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
AU2019350865A1
(en)
|
2018-09-26 |
2021-04-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with Anti-CD19/CD22 immunotherapy
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
EP3860646A1
(en)
|
2018-10-03 |
2021-08-11 |
Avidea Technologies, Inc. |
Aromatic ring substituted amphiphilic polymers as drug delivery systems
|
WO2020090979A1
(ja)
|
2018-10-31 |
2020-05-07 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
WO2020113108A1
(en)
|
2018-11-30 |
2020-06-04 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd38 immunotherapy
|
MX2021005878A
(es)
|
2018-12-13 |
2021-07-16 |
Eisai R&D Man Co Ltd |
Modulador de empalme de herboxidieno de conjugados de anticuerpo-farmaco y metodos de uso.
|
CN113710271A
(zh)
|
2019-02-05 |
2021-11-26 |
西根股份有限公司 |
抗cd228抗体和抗体-药物缀合物
|
CA3132185A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
CA3132660A1
(en)
|
2019-03-06 |
2020-09-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
BR112021018608A2
(pt)
|
2019-03-20 |
2021-11-23 |
Univ California |
Anticorpos para claudina-6 e conjugados de fármaco
|
CN114585388A
(zh)
|
2019-04-17 |
2022-06-03 |
阿维迪科技公司 |
用于配体展示和/或药物递送的星形聚合物的组合物和制造方法
|
WO2020216947A1
(en)
|
2019-04-24 |
2020-10-29 |
Heidelberg Pharma Research Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
WO2020243546A1
(en)
|
2019-05-30 |
2020-12-03 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
WO2020247572A1
(en)
|
2019-06-05 |
2020-12-10 |
Seattle Genetics, Inc. |
Masked antibody formulations
|
AR119097A1
(es)
|
2019-06-05 |
2021-11-24 |
Seattle Genetics Inc |
Métodos de purificación de anticuerpos enmascarados
|
EP3994173A1
(en)
|
2019-07-02 |
2022-05-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
TW202116810A
(zh)
|
2019-07-22 |
2021-05-01 |
美商西雅圖遺傳學股份有限公司 |
用於治療癌症之人化抗liv1抗體
|
CN114650843A
(zh)
|
2019-10-04 |
2022-06-21 |
Tae生命科学有限责任公司 |
包括fc突变和位点特异性缀合性质的抗体组合物
|
BR112022005114A2
(pt)
|
2019-10-04 |
2022-06-21 |
Seagen Inc |
Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
|
EP3812008A1
(en)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-competitive antagonist antibody
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
EP4087657A1
(en)
|
2020-01-08 |
2022-11-16 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
WO2021228956A1
(en)
|
2020-05-12 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
TW202210517A
(zh)
|
2020-06-05 |
2022-03-16 |
日商衛材R&D企管股份有限公司 |
抗bcma抗體-藥物軛合物及其使用方法
|
WO2021251358A1
(ja)
|
2020-06-09 |
2021-12-16 |
味の素株式会社 |
修飾フェリチンおよびその製造方法
|
US11497770B2
(en)
|
2020-06-22 |
2022-11-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
|
US20230295330A1
(en)
|
2020-08-04 |
2023-09-21 |
Seagen Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
CA3193244A1
(en)
|
2020-09-22 |
2022-03-31 |
Geoffrey Martin Lynn |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
WO2022067348A1
(en)
|
2020-09-28 |
2022-03-31 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
CA3197168A1
(en)
|
2020-10-01 |
2022-04-07 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
US20230390406A1
(en)
|
2020-10-19 |
2023-12-07 |
Vaccitech North America, Inc. |
Star Polymer Drug Conjugates
|
CA3196243A1
(en)
|
2020-10-20 |
2022-04-28 |
Angela Marinetti |
Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
|
AU2021372997A1
(en)
|
2020-11-05 |
2023-06-22 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
EP4279502A1
(en)
|
2021-01-18 |
2023-11-22 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained therefrom
|
KR20230133294A
(ko)
|
2021-01-18 |
2023-09-19 |
아지노모토 가부시키가이샤 |
화합물 또는 그 염, 및 그것들에 의해 얻어지는 항체
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CA3207998A1
(en)
|
2021-02-16 |
2022-08-25 |
Geoffrey M. Lynn |
Self-assembling nanoparticles based on amphiphilic peptides
|
WO2022192403A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Cd3及びgpc3に結合するヘテロ二量体抗体
|
AU2022234694A1
(en)
|
2021-03-11 |
2023-09-21 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained using same
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
JPWO2022196675A1
(pt)
|
2021-03-16 |
2022-09-22 |
|
|
CA3208117A1
(en)
|
2021-03-19 |
2022-09-22 |
Torsten HECHLER |
B-lymphocyte specific amatoxin antibody conjugates
|
AU2022250810A1
(en)
|
2021-03-30 |
2023-11-09 |
Legochem Biosciences, Inc. |
Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
|
JP2024518709A
(ja)
|
2021-04-10 |
2024-05-02 |
プロファウンドバイオ ユーエス カンパニー |
Folr1結合剤、そのコンジュゲートおよびこれを使用する方法
|
EP4322746A1
(en)
|
2021-04-15 |
2024-02-21 |
Abionyx Pharma SA |
Use of lipid binding protein-based complexes in organ preservation solutions
|
AU2022262644A1
(en)
|
2021-04-23 |
2023-11-09 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
WO2023288236A1
(en)
|
2021-07-14 |
2023-01-19 |
Seagen Inc. |
Antibody masking domains
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
WO2023054706A1
(ja)
|
2021-09-30 |
2023-04-06 |
味の素株式会社 |
抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
WO2024092028A2
(en)
|
2022-10-25 |
2024-05-02 |
Vaccitech North America, Inc. |
Combination treatment regimes for treating cancer
|
WO2024092030A1
(en)
|
2022-10-25 |
2024-05-02 |
Vaccitech North America, Inc. |
Self-assembling nanoparticles
|